p16ink4a gene and hematological malignancies

Leukemia and Lymphoma

Volumn 22, Issue 1-2, 1996, Pages 11-24

  Quesnel, Bruno ^a,b   Preudhomme, Claude ^a,b   Fenaux, Pierre ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Institut de Recherche sur le Cancer de Lille   (France)

Author keywords

Hematological malignancy; P16ink 4a gene

Indexed keywords

CYCLIN DEPENDENT KINASE; PROTEIN KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; CARRIER PROTEIN; CDKN2B PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA; PROTEIN P16INK4A; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLAST CELL CRISIS; CANCER GENETICS; CELL CYCLE; CHROMOSOME 9P; CHRONIC MYELOID LEUKEMIA; DIGESTIVE SYSTEM CANCER; GENE; GENE DELETION; HUMAN; LEUKEMIA; MELANOMA; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; T CELL LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AMINO ACID SEQUENCE; BIOLOGICAL MODEL; BLOOD DISEASE; CANCER STEM CELL; CHROMOSOME 9; CYTOLOGY; ENZYME ACTIVATION; FEEDBACK SYSTEM; GENETICS; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

ADULT; AMINO ACID SEQUENCE; BLAST CRISIS; CARRIER PROTEINS; CELL CYCLE; CELL CYCLE PROTEINS; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; DNA, NEOPLASM; ENZYME ACTIVATION; FEEDBACK; GENE DELETION; GENES, TUMOR SUPPRESSOR; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; POINT MUTATION; TUMOR STEM CELLS; TUMOR SUPPRESSOR PROTEINS;

EID: 0029665954     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199609051724     Document Type: Article

References (126)

1. Hartwell, L. H. and Kastan, M. B. (1994) Cell cycle control and cancer. Science, 266, 1821-1828.
2. Hunter, T. and Pines, J. (1994) Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell, 79, 573-582.
3. Ando, K. and Griffin, J. D. (1995) Cdk4 integrates growth stimulatory and inhibitory signals during G1 phase of hematopoietic cells. Oncogene, 10, 751-755.
4. Lukas, J., Bartkova, J., Welcker, M., Petersen, O. W., Peters, G., Strauss, M. and Bartek, J. (1995) Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene, 10, 2125-2134.
5. Shiekhattar, R., Mermelstein, F., Fisher, R. P., Drapkin, R., Dynlacht, B., Wessling, H. C., Morgan, D. O. and Reinberg, D. (1995) Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature. 374, 283-287.
6. Murray, A. (1995) Cyclin ubiquitination. the destructive end of mitosis. Cell. 81, 149-152.
7. Peters, M. and Herskowitz, I. (1994) Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell, 79, 181-184.
8. Sherr, C. J. and Roberts, J. M. (1995) Inhibitors of mammalian G1 cyclin-dependent kinases Genes dev., 9, 1149-1163.
9. Peters, M., Gartner, A., Horecka, J., Ammerer, G. and Herskowitz, I. (1993) FARI links the signal transaction pathway to the cell cycle machinery in yeast. Cell, 73, 747-760.
10. SICI controls the G1 to S transition in S. cerevisiae. Cell, 79, 233-244.
11. + gene. Nature, 367, 236-242.
12. Hannon, G. J., Casso, D. and Beach, D. (1994) KAP: A dual specificity phosphatase that interacts with cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA. 91, 1731-1735.
13. Kipt to regions involved in human cancer. Cancer Res., 55, 1199-1205.
14. kipt a cyclin-cdk inhibitor links transforming growth factor-b and contact inhibition to cell cycle arrest. Genes Dev., 8, 9-22.
15. Kipt cyclin-dependent kinase inhibitor prevented by rapamycin. Nature, 372, 570-573.
16. Kipl) of cyclin-dependent kinase 4 activation. Cell, 79, 487-496
17. 1,2 Cancer res., 55, 1413-1416.
18. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
19. Cipl. Nature, 375, 159-161.
20. Chen, J., Jackson, P. K., Kirschner, M. W.and Dutta, A. (1995) Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature, 374, 386-388.
21. Fisher, D. E., Bodis, S., Lowe, S., Takemoto, C., Housman, D. and Jacks, T. (1994) Restoration of apoptosis in p53 deficient tumor cells Blood, 84, sup.1, Ab 429.
22. Skapek, S. X., Rhee, J., Spicer, D. B. and Lassar, A. B. (1995) Inhibition of myogenic differentiation in proliferating myoblasts by cyclin Dl-dependent kinase. Science, 267, 1022-1024.
23. Halevy, O., Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G. J., Beach, D. and Lassar, A. B. (1995) Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science, 267, 1018-1021.
24. Steinman, R. A., Hoffman, B., Iro, A., Guillouf, C., Liebermann, D. A. and El-Houseini, M. E. (1994) Induction of p21 (WAF-I/CIPI) during differentiation. Oncogene, 9, 3389-3396.
25. Cipl in muscle and other terminally differentiating cells. Science, 267, 1024-1027.
26. CIPI Cdk inhibitor family, is a condidate tumor suppressor gene. Genes dev., 9, 650-662.
27. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes dev., 9, 639-649.
28. Serrano, M., Hannon, G. J. and Beach, D. (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366, 704-707.
29. INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature, 371, 257-261.
30. Ink4. Cancer Res., 54, 5816-5820.
31. Bremmer, R., Cohen, B. L., Sopta, M., Hamel, P. A., Ingles, C. J., Gallie, B. L. and Phillips, R. A. (1995) Direct transcriptional repression by pRB and its reversal by specific cyclins. Mol. Cell. Biol., 15, 3256-3265.
32. 1 control in retinoblastoma genedeficient cells independently of cdk4 activity. Mol. Cell. Biol., 15, 2600-2611.
33. 1. Cancer Res., 54, 6078-6082.
34. INK4, the product of the putative tumor suppressor gene MTS1. Oncogene, 9, 3475-3482.
35. Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G. and Bartek, J. (1995) Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature, 375, 503-506.
36. INK4/MTS1 tumour suppressor gene product. EMBO J., 14, 503-511.
37. Yeager, T., Stadler, W., Belair, C., Puthenveettil, J., Olopade, O. and Reznikoff, C. (1995) Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res., 55, 493-497.
38. INK4 expression in primary lung cancers and cell lines. Cancer Res., 55, 505-509.
39. INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene, 9, 3375-3378.
40. INK4B/MTS2, and p18 genes in primary and metastatic Iung cancer. Cancer Res., 55, 1448-1451.
41. INK4B/MTS2-relatedel CDK6 inhibitor, correlated with wild-type pRb function. Genes & Development. 8, 2939-2952.
42. Hirai, H., Roussel, M. F., Kato, J. Y., Ashmun, R. A. and Sherr, C. J. (1995) Novel INK4 proteins. p19 and P718, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol., 15, 2672-2681.
43. ink4.mol. Cell. Biol., 15. 2682-2688.
44. ink4a transcript. Cancer Res., 55, 2995-2997.
45. ink4a locus. Cancer Res., 55, 2998-2994.
46. lnk4a/MTS1 gene transcript expressed in B-cell malignancies. Oncogene, 11, 21-29.
47. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stocken, E., Day R. S., Johnson, B. E. and Skolnick, M. H. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440.
48. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K. and Carson, D. A. (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature, 368, 753-756.
49. INK4 deletions with monosomy 5 in kidney epithelial cell lines but not primary renal tumors. Cancer Res., 55, 1607-1612.
50. INK4 deficiency in multiple tumor cell lines. Oncogene, 10, 827-833.
51. Liu, Q., Neuhausen, S., Mc Clure, M., Frye, C.; Weaver-Feldhaus, J.. Gruis, N. A., Eddington, K., Allalunis-Turner, M. J., Skolnick, M. H., Fujimura, F. K. and Kamb, A. (1995) CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene, 10, 1061-1067.
52. Liu, Q., Van, Y.-X., Mc Clure, M., Nakagawa, H., Fujimura, F. and Rustgi, A. K. (1995) MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocaminoma cell lines. Oncogene, 10, 619-622.
53. Beltinger, C. P., White, P. S., Sulman, E. P., Maris, J. M. and Brodeur, G. M. (1995) No CDKN2 mutations in neuroblastomas. Cancer Res., 55, 2053-2055.
54. He, J., Allen, J. R., Collins, V. P., Allalunis-Turner, M. J., Godbout, R., Day, R. S. and James, C. D. (1994) CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res., 54, 5804-5807.
55. Quesnel, B., Fenaux, P., Preudhomme, C., Phillipe, N., Fournier, J. and Peyrat, J. P. Analysis of p16 gene deletion and point mutation in breast carcinoma. British Journal of Cancer (in Press)
56. ink4) in human breast carcinomas. Cancer Res., 54, 5262-5264.
57. Washimi, O., Nagauke, M., Osada, H., Ueda, R., Koshikawa, T., Seki, T., Takahashi, T. and Takahashi, T. (1995) In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res., 55, 514-517.
58. Moulton, T., Samara, G., Chung, W.-Y., Yuan, L., Desai, R., Sisti, M., Bruce, J. and Tycko, B. (1995) MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am. J. Pathol., 146, 613-619.
59. Caldas, C., Hahn, S. A., Da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J. and Kern, S. E. (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genetics, 8, 27-32.
60. Walker, D. G., Duan, W., Popovic, E. A., Kaye, A. H., Tomlinson, F. H. and Lavin, M. (1995) Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res., 55, 20-23.
61. Jen, J., Harper, J. W., Bigner, S. H., Bigner. D. D., Papadopoulos, N., Markowitz, S., Willson, J. K. V., Kinzler, K. W. and Vogelstein, B. (1994) Deletion of p16 and p15 genes in brain tumors. Cancer Res., 54, 6353-6358.
62. Giani, C. and Finocchiaro, G. (1994) Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res., 54, 6338-6339.
63. Spruch-C. H., Gonzalez-Zuelta, M., Shibata, A., Simoneau, A. R., Lin, M. F., Gonzales, F., Tsai, Y. and Jones, P. A. (1994) p16 gene in uncultured tumours. Nature, 370, 183-184.
64. Cheng, J. Q., Jhanwar, S. C., Lu, Y. Y. and Testa, J. R. (1993) Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas Cancer Res.. 53, 4761-4763.
65. Lo, K.-W., Huang, D. P. and Uu, K.-M. (1995) p16 gene alterations in nasopharyngeal carcinoma. Cancer Res., 55, 2039-2043.
66. Zhang, S.-Y., Klein-Szanto, A. J. P., Sauter, E. R., Shafarenko, M., Mitsunaga, Nobori, T., Carson, D. A., Ridge, J. A. and Goodrow, T. L. (1995) Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res., 54, 5050-5053.
67. Cairns, P., Mao, L., Merlo, A., Lee, D. J., Schwab, D., Eby, Y., Tokino, K., Van der Riet, P., Blaugrund, J. E. and Sidransky, D. (1994) Rates of p16(MTS1) mutations in primary tumors with 9p loss. Science, 265, 415-416.
68. Cheng, J. Q., Jhanwar, S. C., Klein, W. M., Bell, D. W., Lee, W. C., Altomare, D. A., Nobori. T., Olopade, O. I., Buckler, A. J. and Testa, J. R. (1994) p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res., 54, 5547-5551.
69. 1. Cancer Res., 55, 2150-2157.
70. Reed, J. A., Loganzo, F., Shea, C. R., Walker, G. J., Flores, J. F., Glendening, M., Bogdany, J. K., Shiel, M. J., Haluska, F. G., Fountain, J. W. and Albino, A. P. (1995) Loss of expression of the p16/Cyclin-dependent kinasc inhibitor 2 tumor Suppressor Gene in Melanocytic lesions correlates with invassive stage of tumor progression. Cancer Res., 55, 2713-2718.
71. ink4b genes in biliary tract cancers. Cancer research, 55, 2756-2760.
72. Zhou, X., Tarmin, L., Yin, J., Jiang, H. Y., Suzuki, H., Rhyu, M. G., Abraham, J. M. and Meltzer, S. J. (1994) The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene, 9, 3737-3741.
73. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A. and Dracopoli, N. C. (1994) Germline p16 mutations in familial melanoma. Nature Genet., 8, 15-21.
74. INK4 function. Nature Genet., 10, 114-115.
75. Gruis, N., Van der Velden, P. A., Sandkuij, L. A., Prins, D. E., Feldbaus, J. W., Kamb, A., Bergman, W. and Frants, R. R. (1995) Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet., 10, 351-353.
76. Ohta, M., Nagai, H., Shimizu, M., Rasio, D., Berd, D., Mastrangelo, M., Singh, A. D., Shields, J. A., Shields, C. L., Croce, C. M. and Huebner, K. (1994) Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK41, in melanoma. Cancer Res., 54, 5269-5272.
77. Mac Geoch, C., Bishop, J. A. N., Bataille, V., Bishop, D. T., Frischauf, A. M., Meloni, R., Cuzick, J., Pinney, E. and Spurr, N. K. (1994) Genetic heterogeneity in familial malignant melanoma. Hum. Mol. Genet., 3. 2195-2200.
78. INK4a gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet., 8, 22-26.
79. Koh, J., Enders, G. H., Dynlacht, B. D. and Harlow, E. (1995) Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature, 375, 506-510.
80. INK4a tumor suppressor protein, Cancer Res., 55, 2503-2506.
81. Sun, Y., Hildesheim, A., Lanier, A. E. P., Cao, Y., Yao. K. T., Raab-Traub, N. and Yang, C. S. (1995) No point mutation byt decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas. Oncogene, 10, 785-788.
82. INK4 expression is frequent in high grade gliomas. Cancer Res., 55, 1941-1945.
83. Islam, M. Q., Islam, K., Levan, G. and Horvath, G. (1995) Monochromosome transfers to Syrian hamster BHK cells via microcell fusion provide functional evidence for suppressor genes on human chromosome 9 both for anchorage independence and for tumorigenicity. Genes, Chromosomes & Cancer, 12, 115-125.
84. INK4 in human cancer. Proc. Natl. Acad. Sci. U.S.A., 91, 11045-11049.
85. INK4. Science, 267, 249-252.
86. Arap, W., Nishikawa, R., Furnari, F. B., Cavenee, W. K. and Su Huang, H. J. (1995) Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res., 55, 1351-1354.
87. Pollak, C. and Hagemeijer, A. (1987) Abnormalities of the short arm of chromosome 9 with partial loss of material in hematological disorders. Leukemia, 1, 541-548.
88. Carroll, A. J., Castleberry, R. P. and Crist, W. M. (1987) Lack of association between abnormalities of the chromosome 9 short arm and either "lymphomatous" features of T cell phenotype in childhood acute lymphocytic leukemia. Blood, 69, 735-738.
89. Offit, K., Parsa, N. Z., Jhanwar, S. C., Filippa, D., Wachtel, M. and Chaganti, R. S. K. (1993) Clusters of chromosome 9 aberrations are associated with clinico-pathologic subsets of non Hodgkin's Lymphoma. Genes Chromosom. Cancer, 7, 1-7.
90. Offit, K., Parsa, N. Z., Jhanwar, S. C., Filippa, D., Wachtel, M. and Chaganti, R. S. K. (1992) t(9;14) denotes a subset of low grade non-Hodgkin's Lymphoma with plasmacytoid differentiation. Blood, 80, 2594-2599.
91. Lillington, D. M., Monard, S., Johnson, P. W. M., Evans, M. L., Kearney, L. U., Lister, T. A., Young, B. D. and Gibbons, B. (1994) The t(14;18) in a patient with de novo acute lymphoblastic leukemia is associated with t(8;9) Leukemia, 8, 560-563.
92. Levine, E. G., Arthur, D. C., Machiniicki, J., Frizzera, G., Hurd, D., Pelerson, B., Gajl-Pelzalska, J. and Bloomfield, C. D. (1989) Four new recurring translocations in non Hodgkin's Lymphoma. Blood, 74, 1796-.
93. Chilcote, R. R., Brown, E. and Rowley, J. D. (1985) Lymphoblastic leukemia with lymphopatous features associated with abnormalities of the short arm of chromosome 9. New Engl. J. Med., 286-291.
94. Lai, J. L., Fenaux, P., Pollet, J. P., Estienne, M. H., Savary, J. B., Huart, J. J. and Deminatti, M. (1988) Acute lymphocytic leukemia with 9p anomalies. A report of four additional cases and review of the literature. Cancer Genet. Cylogenet., 33, 99-109.
95. Diaz, M. O., Rubin, C. M., Harden, A., Ziemin, S., Larson, R. A., Le Beau, M. M. and Rowley, J. D. (19..) Deletions of Interferon genes in acute lymphoblastic leukemia. New Engl. J. Med., 322, 77-82.
96. Ogawa, S., Hirano, N., Sato, N., Takahashi, T., Hangaishi, A., Tanaka, K., Kurokawa, M., Tanaka, T., Mitani, K., Yazaki, Y. and Hirai, H. (1994) Homozygous loss in the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood, 84, 2431-2435.
97. INK4B) dysplay frequent homozygos deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemias. Blood, 84, 4038-4044.
98. Quesnel, B., Preudhomme, C., Philippe, N., Vanrumbeke, M., Dervite, I., Lai, J. L., Bauters, F., Wattel, E. and Fenaux, P. (1995) p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood, 85, 657-663.
99. Stranks, G., Height, S. E., Mitchell, P., Jadayel, D., Yuille, Ma. R., De Lord, C., Clutterbuck, R. D., Treleaven, J. G., Powles, R. L., Nacheva, E., Oscier, D. G., Karpas, A., Lenoir, G. M., Smith, S. D., Millar, J. L., Catovsky, D. and Dyer, M. J. S. (1995) Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood, 85, 893-901.
100. INK4B/MTS2 in human leukemias and lymphomas. Cancer Res., 55, 1436-1440.
101. Still, H., Goldman, J. M. and Cross, N. C. P. (1995) Homozygous deletions in the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood, 85, 2013-2016.
102. INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood. 85, 2321-2330.
103. Fizzotti, M., Cimino, G., Pisegna, S., Alimena, G., Quartarone, C., Mandelli, F., Pelicci, P. G. and Lo Coco, F. (1995) Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood, 85, 2685-2690.
104. ink4 gene inactivation in acute lymphocytic leukemia. Blood, 85, 3431-3436.
105. ink4b gene deletions in primary leukemias. Blood, 86, 311-315.
106. Takeuchi, S., Bartram, C. R., Seriu, T., Miller, C. W., Tobler, A., Janssen, J. W. G., Reiter. A., Ludwig, W. D., Zimmermann, M., Schwaller, J., Lee, E., Miyoshi, I. and Koeffler, P. (1995) Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood, 86, 755-760.
107. ink4a/MTS1) gene structure andexpression in acute lymphoblastic leukemias. Leukemia. 9, 1240-1245.
108. Diaz, M. O., Pomykala, H. M., Bohlander, S. K., Maltepe, E., Malik, K., Brownstein, B. and Olopade, O. I. (1994) Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics, 22, 540-552.
109. Hsiao, M. H., Yu, A. L., Yeargin, J., Ku, D. and Haas, M. (1994) Non hereditary p53 mutations in T-cell Acute Lymphoblastic Leukemia are associated with the relapse phase Blood, 83, 2922-2930.
110. Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P. and Fenaux, P. (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematological malignancies. Blood, 84, 3148-3157.
111. Döhner, H., Fisher, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., Volkman, M., Galle, P. R., Poutska, A., Hunstein, W. and Lichter P. (1995) p53 gene deletion predicts for poor survival and non response to therapy with purine analogs in Chronic B-CII leukemia. Blood. 85. 1580-1589.
112. Hata, Y., Hirama, T., Miller, C. W., Yamada, Y., Tomonaga, M. and Koeffler, P. (1995) Homozygous deletions in the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood, 85, 2699-2704.
113. Nakai, H., Misawa, S., Toguchida, J., Yandel, D. W. and Ishizaki, K. (1992) Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of chromosome 17p. Cancer Res., 52, 6588-.
114. Fenaux, P., Jonveaux, P., Quiquandon, I., Laï, J. L., Pignon, J. M., Loucheux Lefebvre, M. H., Bauters, F. and Kerckaert, J. P. (1991) p53 gene mutations in myeloid leukemia with 17p monosomy. Blood, 80, 1652-1657.
115. Gaidano, G., Ballerini, P., Gong, J. Z., Inghirami, G., Neri, A., Newcomb, E. W., Magrath, I. T., Knowles, D. M. and Dalla-Favera, R. (1991) p53 mutations in human lymhoid malignancies associated with Burkitt's lymphoma and chronic lymphocytic leukemia. Proc. Nat. Acad. Sci. USA, 88, 5413-5417.
116. Sander, C. A., Yano, T., Clark, H. M., Harris, C., Longo, D. L., Jaffe, E. S. and Raffeld, M. (1993) p53 mutation is associated with progression in follicular lymphomas. Blood, 82, 1994-2004
117. Golub, T. R., Barker, G. F., Lovett, M. and Gilliland, G. (1994) Fusion of PDGF receptor B to a novel ets-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell, 77, 307-316.
118. Wlodarska, C., Meccucci, C., Marynen, P., Guo, C., Franckx, D., La Starza, R., Aventin, A., Bosly, A., Martelli, M. F., Cassiman, J. J. and Van Den Berghe, H. (1995) TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33:p13) translocation or its variants t(10;12)(q24;p13). Blood, 85, 2848-2852.
119. Kipl gene to 12p13 and its analysis in leukemias. Cancer Res., 55, 1206-1210.
120. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res., 55, 1211-1214.
121. Delmer, A., Ajchenbaum-Cymbalista, F., Tang, R., Ramond, S., Faussat, A. M., Marie, J. P. and Zittoun, R. (1995) Overexpression of cyclin D2 in Chronic B-Cell malignancies. Blood, 85, 2870-2876.
122. De Boer, C. J., Loyson, S., Kluin, P. M., Kluin-Nelemans, H. C., Schuuring, E. and Van Krieken, J. H. J. M. (1993) Multiple breakpoints within the BCL1 locus in B-Cell Lymphoma: Rearrangements of thecyclin D1 gene. Cancer Res., 53, 4148-4152.
123. Jadayel, D., Matutes, E., Dyer, M. J. S., Brito-Babapulle, V., Khohkar, M. T., Oscier, D. and Catowski, D. (1994) Splenic lymphoma with villous lymphocytes: analysis of BCL1 rearrangements and expression of the cyclin D1 gene. Blood, 83, 3664-
124. Furukawa, Y., Terui, Y., Sakoe, K., Ohta, M., Kitagawa, S., Miura, Y. and Saito, M. (1995) Over-expression and amplification of the CDC2 gene in leukaemia cells. Br. J. Haematol., 90, 94-99.
125. Aplan, P. D., Lombardi, D. P., Ginsberg, A. M., Cossman, J., Bertness, V. L. and Kirsh, I. R. (1990) Disruption of the human SCL locus by illegitimate VDJ recombinase activity. Science, 250, 1426.
126. Brown, L., Cheng, J. T., Chen, Q., Siliciano, M. J., Crist, W., Buchanan, G. and Baser, R. (1990) Site specific recombination of the tal I gene is a common occurence in human T cell leukemia. EMBO J., 9, 3343.